HEAL Initiative: Neonatal Opioid Withdrawal Syndrome Pharmacological Treatments Comparative Effectiveness Trial New Mexico Site

HEAL Initiative：新生儿阿片类药物戒断综合征药物治疗效果比较试验新墨西哥州网站

• 批准号: 10891302
• 负责人: LAWRENCE M LEEMAN
• 金额: $ 22.27万
• 依托单位: UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-17 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10891302
• 关键词: HEAL; Initiative; Neonatal; Opioid; Withdrawal

Project Summary/Abstract The Neonatal Opioid Withdrawal Syndrome (NOWS) Pharmacological Treatments Comparative Effectiveness Trial is a multisite study that examine the long- and short-term outcomes for neonates with NOWS that require pharmacological treatment. The neonates will be randomized to three medications: buprenorphine, methadone and morphine. Short term outcomes are anticipated to include length of hospital stay and length of pharmacological treatment, with longer term outcomes including neonatal growth and neurodevelopment. The common protocol will be developed by a steering committee composed of the principal investigators from each participating clinical center. The trial will be designed to control for relevant clinical variables including the type of maternal opioid used, maternal polysubstance use including tobacco, the use of nonpharmacological treatments for NOWS, and the use of adjunctive nonopioid medications. The follow-up plan will be developed as part of the protocol and will extend until at least 24 months of age and include the use of specific neurodevelopmental assessment tools including the Bayley Scales of Infant and Toddler Development 4th Edition. The trial is designed to determine the optimal pharmacological treatment including the specific medication dosing and weaning regimen. The University of New Mexico Clinical Center will include infants treated for NOWS across all neonatal care sites including the mother baby unit where dyadic room-in care is provided, the intermediate care nursery, and the neonatal intensive care unit. The standardization of pharmacological treatment for NOWS is anticipated to have significant public health benefits including decreasing length of hospital stay, decreasing cost of treatment, and potentially improving long term neurodevelopmental outcomes.

项目总结/摘要 新生儿阿片类戒断综合征（NOWS）的药物治疗比较 有效性试验是一项多中心研究，旨在检查新生儿的长期和短期结局， 需要药物治疗的NOWS。新生儿将随机接受三种药物治疗： 丁丙诺啡美沙酮和吗啡预期短期结局包括住院时间 住院时间和药物治疗时间，长期结局包括新生儿生长， 神经发育共同议定书将由一个指导委员会制定， 各参与临床中心的主要研究者。本试验旨在控制相关的 临床变量包括母体使用阿片类药物的类型，母体使用多种物质，包括烟草， 使用非药物治疗NOWS，以及使用非阿片类药物治疗。的 将制定随访计划作为方案的一部分，并将延长至至少24月龄， 包括使用特定的神经发育评估工具，包括贝利婴儿量表， 幼儿发展第四版该试验旨在确定最佳的药物治疗 包括具体的药物剂量和断奶方案。新墨西哥州大学临床中心 将包括在所有新生儿护理中心接受NOWS治疗的婴儿，包括母婴病房， 提供双人病房护理、中级护理托儿所和新生儿重症监护室。的 NOWS的药物治疗标准化预计将对公众健康产生重大影响。 好处包括缩短住院时间，降低治疗费用，并可能改善 长期的神经发育结果。